Amgen (NASDAQ:AMGN) has been given a $192.00 price target by stock analysts at Mizuho in a note issued to investors on Thursday. The firm currently has a “buy” rating on the medical research company’s stock. Mizuho’s price target would suggest a potential upside of 9.56% from the stock’s previous close.
Other research analysts have also issued reports about the company. Oppenheimer reaffirmed a “buy” rating and issued a $203.00 target price on shares of Amgen in a research report on Thursday, September 7th. Royal Bank of Canada started coverage on Amgen in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 target price on the stock. BMO Capital Markets reaffirmed a “hold” rating and issued a $199.00 target price on shares of Amgen in a research report on Monday, September 25th. Jefferies Group reaffirmed a “buy” rating and issued a $200.00 target price on shares of Amgen in a research report on Monday, September 25th. Finally, Credit Suisse Group reaffirmed a “neutral” rating and issued a $186.00 target price (up from $177.00) on shares of Amgen in a research report on Friday, September 29th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $189.94.
Shares of Amgen (NASDAQ:AMGN) traded down $0.96 during trading hours on Thursday, reaching $175.25. The company’s stock had a trading volume of 1,637,700 shares, compared to its average volume of 3,178,188. The firm has a market cap of $127,912.71, a PE ratio of 15.86, a PEG ratio of 2.55 and a beta of 1.36. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. Amgen has a 52-week low of $145.62 and a 52-week high of $191.10.
Amgen announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, October 25th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.
In related news, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The disclosure for this sale can be found here. Insiders have sold 8,575 shares of company stock valued at $1,509,339 over the last 90 days. Insiders own 0.19% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Financial Advisory Service Inc. raised its holdings in Amgen by 0.3% during the second quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock worth $340,000 after purchasing an additional 5 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its holdings in Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares in the last quarter. Capital Advisors Ltd. LLC raised its holdings in Amgen by 0.6% during the second quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock worth $190,000 after purchasing an additional 7 shares in the last quarter. Ballentine Partners LLC raised its holdings in Amgen by 0.3% during the second quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock worth $620,000 after purchasing an additional 9 shares in the last quarter. Finally, Hudock Capital Group LLC raised its holdings in Amgen by 0.5% during the second quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock worth $330,000 after purchasing an additional 10 shares in the last quarter. Institutional investors and hedge funds own 78.46% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was published by American Banking and Market News and is the sole property of of American Banking and Market News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/12/29/amgen-amgn-given-a-192-00-price-target-at-mizuho.html.
About Amgen
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
